Skip to content
Bored Studies
RecruitingPhase 2

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

Pulmovant, Inc. · NCT07333183

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–85 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
20
US sites recruiting
13
Study start
December 23, 2025
Record last updated
September 2, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.

Being studied: inhaled mosliciguat; Dry Powder Inhaler

Conditions: Pulmonary Hypertension; Interstitial Lung Disease (ILD); Lung Diseases; Vascular Diseases; Cardiovascular Diseases; Fibrosis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Participants willing and able to provide informed consent
  • Participants on inhaled treprostinil
  • Participants with diagnosis of Interstitial Lung Disease (ILD). Diagnosis will be confirmed by a high-resolution computerized tomography (HR-CT) scan showing diffuse parenchymal disease. Eligible diagnosed diseases include:
  • Idiopathic interstitial pneumonia (IIP)
  • Chronic hypersensitivity pneumonitis
  • ILD associated with connective tissue disease (CTD) with a forced vital capacity (FVC) \< 70% of predicted
  • Confirmed pulmonary hypertension (PH) by right heart catheterization (RHC).
  • Ability to perform 6MWD ≥100 meters.

Exclusion Criteria

  • Diagnosis of PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related to left-heart dysfunction), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified).
  • Exacerbation of underlying lung disease within 28 days prior to randomization.
  • Initiation of pulmonary rehabilitation within 28 days prior to randomization.
  • Receiving >10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
  • History or intolerance to or lack of efficacy with mosliciguat or sGC stimulators or activators.
  • Receipt of investigational, or experimental therapy within 42 days OR 5 half-lives prior to randomization.

Note: Other inclusion and exclusion criteria may apply.

Recruiting US locations

  • Clinical Research Site

    Santa Barbara, CA 93105

    Site contact: Clinical Site

  • Clinical Research Site

    Torrance, CA 90502

    Site contact: Clinical Site

  • Clinical Research Site

    Kissimmee, FL 34746

    Site contact: Clinical Site

  • Clinical Research Site

    Chicago, IL 60611

    Site contact: Clinical Site

  • Clinical Research Site

    Kansas City, KS 66160

    Site contact: Clinical Site

  • Clinical Research Site

    Boston, MA 02115

    Site contact: Clinical Site

  • Clinical Research Site

    Ann Arbor, MI 48109

    Site contact: Clinical Site

  • Clinical Research Site

    Detroit, MI 48202

    Site contact: Clinical Site

  • Clinical Research Site

    Albuquerque, NM 87131

    Site contact: Clinical Site

  • Clinical Research Site

    Greensboro, NC 27403

    Site contact: Clinical Site

  • Clinical Research Site

    Providence, RI 02903

    Site contact: Clinical Site

  • Clinical Research Site

    Charleston, SC 29425

    Site contact: Clinical Site

  • Clinical Research Site

    Houston, TX 77030

    Site contact: Clinical Site

Study contacts (from the official record)

  • Pulmovant · +1-919-462-1310 · clinicaltrials@pulmovant.com
All heart & blood pressure studies in California →
A Study of Mosliciguat in Combination With Inhaled Treprostinil in… (NCT07333183) | Bored Studies